Clinical trials have demonstrated the clinical efficacy of TKIs or ROS1 inhibitors in patients with NSCLC with ROS1 rearrangement confirmed by FISH assays [47,49]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.